Mark Straley News Today

Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve

The firm is offering access in Brazil to a digital assay that provides genomic insights using technology developed in a collaboration with computational pathology firm Paige.

The firm is offering access in Brazil to a digital assay that provides genomic insights using technology developed in a collaboration with computational pathology firm Paige.

AI solution will expand Agendia's testing platform in the Brazilian breast cancer market Digital MammaPrint offers fast turnaround time to molecular diagnostics, delivering actionable information

/PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a multi-year partnership with Agendia N.V., a world leader in precision oncology for breast...

Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced the appointment of healthcare industry veterans Suja Chandrasekaran, MS and Scott Mendel,

123.6GBX +1.31% IP : Inivata Ltd - Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer Link copied Agendia granted co-exclusive distribution rights for RaDaR in North America and Europe Inivata, a leader in liquid biopsy, today announced it has entered a commercialization agreement with Agendia, Inc., a leader in precision onco...

by Bryant Haskins, NCBiotech Writer — April 30, 2021 . RESEARCH TRIANGLE PARK – This “radar” can detect breast cancer. And it may soon be available to clinicians near you. UK-headquartered Inivata, which has a laboratory presence in Research Triangle Park, has entered into a commercialization agreement with Amsterdam-based Agendia, Inc. to distribute Inivata’s RaDaR liquid biopsy assay. The test tracks a set of up to 48 tumor-specific variants in patients’ blood samples to detect...

. This “radar” can detect breast cancer. And it may soon be available to clinicians near you. UK-headquartered Inivata, which has a laboratory presence in Research Triangle Park, has entered into a commercialization agreement with Amsterdam-based Agendia, Inc. to distribute Inivata’s RaDaR liquid biopsy assay. The test tracks a set of up to 48 tumor-specific variants in patients’ blood samples to detect minimal residual disease (MRD) and early relapse in patients with breast cancer. . M...